Produced in collaboration with the Carcinoid Cancer Foundation.
Support for this patient education program was provided by Ipsen.
We’re pleased to bring you a third program designed in collaboration with the Carcinoid Cancer Foundation.
In this new session, Giovanna Joyce Imbesi, pianist and patient advocate who lives with NETs and joined us for our very first program on carcinoid syndrome, moderates a discussion with Grace Goldstein, the Chief Operating Officer of the Carcinoid Cancer Foundation and Dr. Edward Wolin, Professor of Medicine and Director of the Center for Carcinoid and Neuroendocrine Tumors at Icahn School of Medicine at Mount Sinai. The panelists answer questions from the audience and discuss:
- What factors influence how NETs develop over time
- Signs, and symptoms of the disease
- The role that different health care providers play on a NETs care team, and how they work together
- How people facing NETs can communicate symptoms effectively and become an active participant in treatment decisions
If you signed up or attended for one of our previous programs with the Carcinoid Cancer Foundation in 2017 or 2018, you’re pre-registered for this event!
Speakers
Giovanna Joyce Imbesi, MBA
Grace Goldstein
Edward M. Wolin, MD
Giovanna Joyce Imbesi, MBA
Patient Moderator
Giovanna Joyce Imbesi, MBA, a patient advocate, pianist and composer based in Los Angeles, California, was diagnosed with metastatic neuroendocrine carcinoid cancer in 2005. Following her diagnosis, she founded the nonprofit organization, Generate Possibility, and the Los Angeles Carcinoid Neuroendocrine Tumor Society (LACNETS) program. She received the 2016 Warner Advocacy Award in 2016 and the inaugural Leadership Award from the Carcinoid & Neuroendocrine Tumor Program at Cedars-Sinai Medical Center in June 2019. Ms Imbesi frequently speaks on living with neuroendocrine cancer and the healing power of music and was featured as 1 of 6 leaders in Integrative Cancer Care at the 2018 Symington Public Forum at Commonweal. She received her MBA from the UCLA Anderson School of Management in 2013.Grace Goldstein
Cardinoid Cancer Foundation (CCF)
Grace Goldstein is Chief Operating Officer of the Carcinoid Cancer Foundation, where she has worked for 16 years. Grace represents CCF on the International Neuroendocrine Cancer Alliance (INCA). CCF is one of the founding members of the organization. Grace was chosen by her colleagues to be the first President of INCA in 2013 and has also served on INCA’s Board of Directors. She currently chairs INCA’s Membership Committee. In 2014, she received the Warner Award for Patient Advocacy, presented by Novartis Oncology. The award was established in 2009 to commemorate the life and work of the late Monica Warner. Prior to joining the staff at CCF, Grace was Director of Public Information and Alumni Affairs at the State University of New York at Purchase and she has also been an indexer, copy editor, and proofreader for many major publishing companies.
Edward M. Wolin, MD
Icahn School of Medicine at Mount Sinai
Edward M. Wolin, MD, an internationally-renowned authority on neuroendocrine tumors, is the director of the Center for Carcinoid and Neuroendocrine Tumors and a professor of medicine, hematology and medical oncology at the Icahn School of Medicine at Mount Sinai in New York. Dr Wolin has pioneered innovative therapies with novel somatostatin analogs, mTOR inhibitors, anti-angiogenic drugs, and peptide receptor radiotherapy. He is co-medical director for the Carcinoid Cancer Foundation, is on the Carcinoid Cancer Research Grants Scientific Review Committee for the American Association for Cancer Research and is a reviewer for numerous journals, including the Journal of Clinical Oncology, Molecular Cancer Therapeutics, Clinical Cancer Research, and The Lancet Oncology.
-
Giovanna Joyce Imbesi, MBA
Patient Moderator
Giovanna Joyce Imbesi, MBA, a patient advocate, pianist and composer based in Los Angeles, California, was diagnosed with metastatic neuroendocrine carcinoid cancer in 2005. Following her diagnosis, she founded the nonprofit organization, Generate Possibility, and the Los Angeles Carcinoid Neuroendocrine Tumor Society (LACNETS) program. She received the 2016 Warner Advocacy Award in 2016 and the inaugural Leadership Award from the Carcinoid & Neuroendocrine Tumor Program at Cedars-Sinai Medical Center in June 2019. Ms Imbesi frequently speaks on living with neuroendocrine cancer and the healing power of music and was featured as 1 of 6 leaders in Integrative Cancer Care at the 2018 Symington Public Forum at Commonweal. She received her MBA from the UCLA Anderson School of Management in 2013. -
Grace Goldstein
Cardinoid Cancer Foundation
Grace Goldstein is Chief Operating Officer of the Carcinoid Cancer Foundation, where she has worked for 16 years. Grace represents CCF on the International Neuroendocrine Cancer Alliance (INCA). CCF is one of the founding members of the organization. Grace was chosen by her colleagues to be the first President of INCA in 2013 and has also served on INCA’s Board of Directors. She currently chairs INCA’s Membership Committee. In 2014, she received the Warner Award for Patient Advocacy, presented by Novartis Oncology. The award was established in 2009 to commemorate the life and work of the late Monica Warner. Prior to joining the staff at CCF, Grace was Director of Public Information and Alumni Affairs at the State University of New York at Purchase and she has also been an indexer, copy editor, and proofreader for many major publishing companies. -
Edward M. Wolin, MD
Icahn School of Medicine at Mount Sinai
Edward M. Wolin, MD, an internationally-renowned authority on neuroendocrine tumors, is the director of the Center for Carcinoid and Neuroendocrine Tumors and a professor of medicine, hematology and medical oncology at the Icahn School of Medicine at Mount Sinai in New York. Dr Wolin has pioneered innovative therapies with novel somatostatin analogs, mTOR inhibitors, anti-angiogenic drugs, and peptide receptor radiotherapy. He is co-medical director for the Carcinoid Cancer Foundation, is on the Carcinoid Cancer Research Grants Scientific Review Committee for the American Association for Cancer Research and is a reviewer for numerous journals, including the Journal of Clinical Oncology, Molecular Cancer Therapeutics, Clinical Cancer Research, and The Lancet Oncology.
